183500-34-7

Basic information

• Product Name: (1-TRITYL-1H-IMIDAZOL-4-YL)METHYL ACETATE
• Synonyms: (1-TRITYL-1H-IMIDAZOL-4-YL)METHYL ACETATE
• CAS NO: 183500-34-7
• Molecular Formula: C₂₅H₂₂N₂O₂
• Molecular Weight: 0
• Mol File: 183500-34-7.mol
• Article Data: 46

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (1-TRITYL-1H-IMIDAZOL-4-YL)METHYL ACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: (1-TRITYL-1H-IMIDAZOL-4-YL)METHYL ACETATE(183500-34-7)
• EPA Substance Registry System: (1-TRITYL-1H-IMIDAZOL-4-YL)METHYL ACETATE(183500-34-7)

Safety Data

• Hazardous Substances Data: 183500-34-7(Hazardous Substances Data)

Usage

General Description

(1-TRITYL-1H-IMIDAZOL-4-YL)METHYL ACETATE is a chemical compound that is used in various industries, including pharmaceuticals and materials science. It is a derivative of imidazole, a heterocyclic organic compound, and has a trityl (triphenylmethyl) group attached to the imidazole ring. The trityl group provides stability and protection to the imidazole ring, making it useful in organic synthesis and as a protecting group in chemical reactions. Methyl acetate is a common solvent and is used as an intermediate in the production of various chemicals. The combination of the trityl-protected imidazole with methyl acetate results in a versatile compound that has applications in drug development, organic synthesis, and material fabrication.

Upstream product

• 33769-07-2 4-(hydroxymethyl)-1-(triphenylmethyl)imidazole 
• 76-83-5 trityl chloride 

Downstream Products

• 198648-98-5 [3-(4-cyanobenzyl)-3H-imidazol-4-yl]methyl acetate 
• 626242-04-4 (1-benzyl-1H-5-imidazolyl)methyl acetate 
• 833490-35-0 [1-(4-trifluoromethylbenzyl)-1H-5-imidazolyl]methyl acetate 
• 854714-87-7 [1-(4-methylbenzyl)-1H-5-imidazolyl]methyl acetate 
• 833490-36-1 [1-(4-methoxybenzyl)-1H-5-imidazolyl]methyl acetate 

Relevant articles and documents

Design and synthesis of piperidine farnesyltransferase inhibitors with reduced glucuronidation potential

The design and synthesis of a novel piperidine series of farnesyltransferase (FTase) inhibitors with reduced potential for metabolic glucuronidation are described. The various substitution and exchange of the phenyl group at the C-2 position of the previously described 2-(4-hydroxy)phenyl-3-nitropiperidine 1a (FTase IC50 = 5.4 nM) resulted in metabolically stable compounds with potent FTase inhibition (14a IC50 = 4.3 nM, 20a IC50 = 3.0 nM, and 50a IC50 = 16 nM). Molecular modeling studies of these compounds complexed with FTase and farnesyl pyrophosphate are also described.

Potent and selective farnesyl transferase inhibitors

We recently described a novel series of CA1A2X peptidomimetics as farnesyl transferase inhibitors (FTIs). These compounds possess an N-(4-piperidinyl)benzamide scaffold mimicking A1A 2 residue. Extensive exploration of structure-activity relationships revealed that replacement of cysteine by substituted benzylimidazoles provided nanomolar FTIs with in vitro activities (18e, IC50 = 4.60 nM on isolated enzyme, EC50 = 20.0 nM for growth inhibition on a tumor cell line). The molecular docking of 18e and 19e in the active site of the enzyme provided details of key interactions with the protein and showed that the methionine or phenylalanine residue fits into the aryl binding site.

INHIBITORS OF PRENYL-PROTEIN TRANSFERASE

The present invention is directed to peptidomimetic piperazine-containing macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras